Table 1 Summary of the pharmacokinetic data obtained after the oral or intravenous administration of STX243 at two separate doses (10 and 40 mg kg−1)
From: The in vivo properties of STX243: a potent angiogenesis inhibitor in breast cancer
PK parameter | Intravenous (40 mg kg−1) | Oral (40 mg kg−1) | Intravenous (10 mg kg−1) | Oral (10 mg kg−1) |
|---|---|---|---|---|
Cmax (μg ml−1) | 44.85 | 1.76 | 13.14 | 0.64 |
t1/2α (h) | 0.16 | — | 0.38 | — |
t1/2β (h) | 3.18 | 1.88 | 4.78 | 11.40 |
AUC (hμg ml−1) | 126 | 23 | 42 | 13 |
AUMC (h2μg ml−1) | 558 | 157 | 267 | 219 |
MRT (h) | 4.44 | 6.93 | 6.28 | 16.79 |
Cl (ml kg−1 h−1) | 318 | 1764 | 235 | 766 |
VD (l kg−1) | 1.41 | 12.23 | 1.48 | 12.86 |
Bioavailability (% F) | — | 18.0 | — | 30.7 |
